Key Takeaway: Vivani Medical has announced the publication of positive data regarding weight loss associated with its OKV-119 miniature GLP-1 implant. This data supports the potential use of the implant in veterinary applications. The long-term nature of the implant may offer significant benefits for weight management in animals.
Price reaction · baseline $1.67 (2024-05-24 close) · hit pre-market · clean, no other VANI news in the window
day 0 close
-0.6%
Market Sentiment Analysis
POSITIVE FACTORS
Publication of positive weight loss data.
Potential veterinary use of the OKV-119 implant.
Long-term GLP-1 implant shows promise.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~10 mo
Medium dilution risk
Lead asset
Semaglutide
Phase 1 · Obesity & Overweight
Full Press Release Details
Blog Post
| May 28, 2024
Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant
Read More
Previous Article
Next Article
Blog Navigation
Frequently Asked Questions
What is the OKV-119 implant?
The OKV-119 is a miniature, long-term GLP-1 implant developed by Vivani Medical.
What positive data was published?
Vivani Medical published positive weight loss data supporting the use of OKV-119.
What potential applications does OKV-119 have?
The data suggests potential veterinary applications for the OKV-119 implant.
How does the GLP-1 implant work?
The GLP-1 implant aids in weight management by mimicking the effects of GLP-1 hormone.